Literature DB >> 3539172

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.

W Heit, D Bunjes, M Wiesneth, T Schmeiser, R Arnold, G Hale, H Waldmann, H Heimpel.   

Abstract

We have developed a rapid and simple procedure for the elimination of mature T-cells from the donor marrow using a single incubation with the monoclonal antibody Campath-1 and donor complement. This resulted in a reduction of T-cell contamination to a mean of 1%. This regimen reduced the incidence of acute graft-versus-host disease significantly in 21 consecutive bone marrow grafts in 18 patients with leukaemia and non-Hodgkin's lymphoma. Purging was responsible for an increased incidence of graft rejection in HLA-identical transplants (13%).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539172     DOI: 10.1111/j.1365-2141.1986.tb02203.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.

Authors:  T Schmeiser; W Heit; R Arnold; D Bunjes; M Wiesneth; B Hertenstein; W Hampl; H Heimpel
Journal:  Klin Wochenschr       Date:  1987-10-15

2.  Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.

Authors:  Jeanette Lundin; Claes Karlsson; Fredrik Celsing
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.

Authors:  Naval Daver; Susan O'Brien
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

4.  Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow.

Authors:  T Schmeiser; M Wiesneth; D Bunjes; R Arnold; B Hertenstein; W Heit; E Kurrle
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

Review 5.  Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.

Authors:  Joshua M Rosenblum; Allan D Kirk
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

6.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Authors:  Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld
Journal:  Cancer Manag Res       Date:  2012-03-12       Impact factor: 3.989

Review 7.  The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information.

Authors:  P M Wood; S J Proctor
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

Review 8.  The Graft-Versus-Leukemia Effect in AML.

Authors:  Connor Sweeney; Paresh Vyas
Journal:  Front Oncol       Date:  2019-11-19       Impact factor: 6.244

9.  Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).

Authors:  Marco Montillo; Francesca Ricci; Sara Miqueleiz; Alessandra Tedeschi; Enrica Morra
Journal:  Biologics       Date:  2008-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.